At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 182 enrolled

Drug / intervention

Nivolumab +4 morebiological

Likely dose

Not stated in record

Key inclusion· 4

✓Diagnosis of advanced renal cell carcinoma
✓At least 1 measurable lesion
✓Karnofsky Performance Status ≥70%
✓Life expectancy of at least 3 months

Key exclusion· 3

✕Untreated CNS metastases (treated/stable metastases may be allowed)
✕Autoimmune disease
✕Requirement for daily oxygen therapy

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02996110

NCT02996110Phase 2Completed

Compare CT.gov

A Phase 2, Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Participants With Advanced Renal Cell Carcinoma (FRACTION-RCC)

Bristol-Myers Squibb·interventional·Posted Dec 19, 2016·Updated Dec 19, 2022

In Brief

A Phase 2 clinical trial evaluating Nivolumab, Ipilimumab, and 3 other interventions for Advanced Cancer. Completed, enrolled 182 participants across 32 sites in 6 countries.

Detailed Summary

The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsAdvanced Cancer

CountriesAustralia, Austria, Canada, Israel, Italy, United States

Collaborators--

Timeline

Phase 2CompletedFinished

2017201820192020202120222023202420252026

First PostedDec 2016

Enrollment StartFeb 2017

Primary CompletionNov 2021

TodayJul 2026

First PostedDec 19, 2016

Enrollment StartFeb 2, 2017

Primary CompletionNov 23, 2021

TodayJul 2, 2026

Enrollment to primary: 4.8 yearsPosted 9.5 years ago